0.4502
price down icon3.60%   -0.0168
 
loading
Lyell Immunopharma Inc stock is traded at $0.4502, with a volume of 612.64K. It is down -3.60% in the last 24 hours and down -14.28% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$0.467
Open:
$0.459
24h Volume:
612.64K
Relative Volume:
0.65
Market Cap:
$129.27M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-0.5699
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+3.83%
1M Performance:
-14.28%
6M Performance:
-51.43%
1Y Performance:
-79.54%
1-Day Range:
Value
$0.4217
$0.478
1-Week Range:
Value
$0.4217
$0.49
52-Week Range:
Value
$0.3931
$2.875

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Name
Lyell Immunopharma Inc
Name
Phone
650 695-0677
Name
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Employee
300
Name
Twitter
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LYEL
Lyell Immunopharma Inc
0.4502 129.27M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-30-24 Downgrade BofA Securities Buy → Underperform
Jun-27-24 Downgrade H.C. Wainwright Buy → Neutral
Aug-28-23 Downgrade JP Morgan Overweight → Neutral
Nov-14-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-11-22 Downgrade Goldman Buy → Neutral
Oct-17-22 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated BofA Securities Buy
Jul-12-21 Initiated Goldman Buy
Jul-12-21 Initiated JP Morgan Overweight
Jul-12-21 Initiated Morgan Stanley Overweight
View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

pulisher
Apr 24, 2025

A better buy-in window may exist right now for Lyell Immunopharma Inc (LYEL) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 35,640 shares worth 19958.0. - knoxdaily.com

Apr 24, 2025
pulisher
Apr 22, 2025

Can you now get a good deal on Lyell Immunopharma Inc’s shares? - uspostnews.com

Apr 22, 2025
pulisher
Apr 19, 2025

Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Lyell Immunopharma gets FDA RMAT status for lymphoma treatment - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients - Stock Titan

Apr 15, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Cuts Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 - Investing.com

Apr 10, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 07, 2025

CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition - Fierce Pharma

Apr 07, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 By Investing.com - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com

Apr 02, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma to close West Hills facility, cut 73 jobs By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 31, 2025

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025
pulisher
Mar 27, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 200,000 shares worth 0.12 million. - knoxdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Wednesday 3/26 Insider Buying Report: LYEL, LSAK - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey

Mar 25, 2025
pulisher
Mar 23, 2025

Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com

Mar 23, 2025
pulisher
Mar 20, 2025

Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Chief Financial Officer of Lyell Immunopharma Charles Newton Buys 989% More Shares - simplywall.st

Mar 20, 2025
pulisher
Mar 19, 2025

How to interpret Lyell Immunopharma Inc (LYEL)’s stock chart patterns - US Post News

Mar 19, 2025
pulisher
Mar 19, 2025

Lyell Immunopharma stock hits 52-week low at $0.51 By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Lyell Immunopharma director Richard Klausner purchases $94,942 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CFO Newton purchases $111,620 in common stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma stock hits 52-week low at $0.51 - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright - Defense World

Mar 15, 2025
pulisher
Mar 13, 2025

H.C. Wainwright maintains Neutral on Lyell Immunopharma stock By Investing.com - Investing.com Australia

Mar 13, 2025

Lyell Immunopharma Inc Stock (LYEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lyell Immunopharma Inc Stock (LYEL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ramachandra Sumant
Director
Mar 21 '25
Buy
0.58
200,000
115,220
200,000
Klausner Richard
Director
Mar 14 '25
Buy
0.60
158,000
94,942
843,365
Newton Charles W.
Chief Financial Officer
Mar 17 '25
Buy
0.56
200,000
111,620
200,000
Seely Lynn
President and CEO
Mar 14 '25
Buy
0.61
175,000
106,190
712,500
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):